Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Stem Cell Recruitment in Osteoporosis Therapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Suzanne Jan de Beur, MD, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT01656629
First received: August 1, 2012
Last updated: November 21, 2014
Last verified: November 2014
  Purpose

Osteoporosis is an important health problem in the rapidly-aging demographic. Fragility fractures are devastating consequences of osteoporosis. The most common treatment approach in osteoporosis is inhibition of bone resorption with drugs like alendronate (ALN). Parathyroid hormone (PTH) stimulates bone formation and is the only anabolic drug available. Dual therapy with ALN and PTH is not as effective as single-drug therapy in preventing fracture. Bone progenitor cells (MSCs) are recruited to sites of bone remodeling when a growth factor called TGF-β1 is released from bone. Different osteoporosis medicines may have differing effects on this process. The effects of ALN versus PTH on bone progenitor recruitment in humans are unknown. This is a randomized, clinical trial of ALN, PTH, and calcium and vitamin D in post-menopausal women with low bone mass. Women will be treated for 3 months with ALN or PTH or calcium and vitamin D. Data collected will include bone biopsies for histomorphometry and µCT, bone marrow aspirates for molecular studies, peripheral blood to detect circulating bone progenitor cells and dual X-ray absorptiometry. We hypothesize that in humans, PTH will 1) increase bone progenitor number, 2) enhance recruitment of bone progenitor cells to bone resorption sites, and 3) increase bone progenitor number in peripheral circulation. Furthermore, we hypothesize that ALN treatment will have the opposite effect. Understanding the differences in bone progenitor cell activity and recruitment during osteoporosis therapy will provide a mechanistic rationale for effective use of PTH and anti-resorptive drugs in osteoporosis treatment.


Condition Intervention
Low Bone Density
Drug: Teriparatide
Drug: Alendronate
Dietary Supplement: calcium and vitamin D

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label

Resource links provided by NLM:


Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Number of Stro-1+ MSCs at bone resorption sites in bone biopsies of subjects treated with PTH or ALN. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Number of p-Smad 2/3+ cells/mm2 at active resorption sites on bone biopsy specimens of subjects treated with PTH or ALN. [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The percent increase in Stro-1+/CD146+ cells in the blood before and after treatment with PTH or ALN. [ Time Frame: baseline and 2 months ] [ Designated as safety issue: No ]
  • Number of human Stro-1+ MSCs at bone resorption sites in bone of Rag2-/- mice reconstituted with human bone marrow derived from subjects treated with PTH or ALN. [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Enrollment: 46
Study Start Date: August 2012
Study Completion Date: August 2014
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: teriparatide
teriparatide 20 mcg sq for 3 months
Drug: Teriparatide
20 mcg subq daily for 3 months
Active Comparator: Alendronate
70 mg po weekly for 3 months
Drug: Alendronate
70 mg weekly for 3 months
Active Comparator: calcium and vitamin D
calcium 630 mg vitamin D 500 units daily for 3 months
Dietary Supplement: calcium and vitamin D

  Eligibility

Ages Eligible for Study:   50 Years to 80 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Post-menopausal women aged 50-80 years
  • T score < -2.5 at lumbar spine, total hip or femoral neck on dual x-ray absorptiometry (DXA) OR T score < -1.5 with a personal or family history of fracture

Exclusion Criteria:

  • Previous use of bisphosphonates or PTH; current estrogen therapy; any other osteoporosis therapy in the past 6 months
  • Metabolic bone disease other than osteoporosis
  • BMI<18
  • Weight > 325 lbs
  • Current smoking or current alcohol use that exceeds 3 units of alcohol daily
  • Use of medications known to affect bone metabolism
  • Renal disease, history of kidney stones or hypercalciuria
  • Hypo- or hyperparathyroidism; hypo- or hypercalcemia
  • Serum vitamin D level < 20 ng/dL
  • Refusal to adjust their dietary calcium to <750mg (i.e. two servings per day of calcium rich food)
  • History of bone marrow or organ transplant
  • History of malignancy or radiation to the bone
  • History of esophageal stricture, dysmotility or severe reflux disease
  • Gastrointestinal malabsorption
  • Use of digoxin
  • Need for chronic anticoagulation therapy such as Coumadin, heparin or low molecular weight heparin or inability to discontinue anti-platelet medication
  • Bleeding diathesis; hemoglobin ≤ 12.5 g/dL (American Red Cross cut-off to donate blood)
  • INR pro time > 1.1 or APTT ratio > 1.2
  • Platelets < 150K/cu mm
  • Cellulitis at site of iliac crest
  • History of allergy to medications used in bone biopsy (demeclocycline, lidocaine)
  • Inability to understand and provide informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01656629

Locations
United States, Maryland
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
Suzanne Jan de Beur, MD
  More Information

No publications provided

Responsible Party: Suzanne Jan de Beur, MD, Associate Professor of Medicine, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT01656629     History of Changes
Other Study ID Numbers: NA_00050448
Study First Received: August 1, 2012
Last Updated: November 21, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Alendronate
Ergocalciferols
Teriparatide
Vitamin D
Vitamins
Bone Density Conservation Agents
Growth Substances
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 23, 2014